Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2018-10-26 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
2018年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2018 年第三季度报告" which translates to "2018 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and management commentary for the third quarter of 2018. The report includes actual financial figures for the period 1-9 months of 2018 and compares them to the same period in 2017. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content and structure align with an Interim / Quarterly Report, as it covers a period shorter than a full fiscal year and includes substantive financial data and analysis. Therefore, the appropriate classification is Interim / Quarterly Report (IR). 9M 2018
2018-10-26 Chinese
关于获得新兽药注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement by 普莱柯生物工程股份有限公司 regarding the receipt of a new veterinary drug registration certificate for a vaccine product. It includes details about the product, its development, market background, and regulatory procedures still required before market launch. The document is relatively short (1368 characters) and serves as a formal notification of a regulatory approval event rather than a financial report or detailed operational disclosure. There is no financial data, earnings information, or management discussion. It is not a report but an announcement of a regulatory milestone. Therefore, the document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-10-24 Chinese
关于获得新兽药注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from the company 普莱柯生物工程股份有限公司 regarding the receipt of a new veterinary drug registration certificate. It details the product information, development background, market context, and significance to the company. The document is relatively short (2075 characters) and serves as a formal public notice about a regulatory approval rather than a financial report or detailed management discussion. There is no financial data, earnings information, or management changes. It is not a report publication announcement since it contains substantive content about the new drug registration. The document fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about a new product approval and does not fit other more specific categories like Annual Report, Earnings Release, or Management Reports.
2018-10-24 Chinese
关于获得新兽药注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from the company about obtaining a new veterinary drug registration certificate. It details the product information, development background, market context, and regulatory procedures remaining before the product can be marketed. The document is relatively short (1381 characters) and serves as a formal public notice rather than a detailed report or financial statement. It does not contain financial data, management discussion, or regulatory certifications. It is an announcement of a regulatory approval event related to the company's product, fitting best under a general regulatory announcement category rather than a specific financial or management report. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2018-10-24 Chinese
关于收到政府补助的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company about receiving government subsidies, specifying the amount, purpose, and accounting treatment. It does not contain financial statements or detailed financial analysis. The length is only 566 characters, indicating it is a brief announcement rather than a full report. It fits the category of a regulatory announcement about a financial event (government subsidy) impacting earnings but is not a full financial report or earnings release. Therefore, it is best classified as a Regulatory Filing (RNS).
2018-09-21 Chinese
关于对暂时闲置自有资金和募集资金进行现金管理的实施公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company about the use of temporarily idle own funds and raised funds for cash management through purchasing various bank financial products. It includes specifics about the products, amounts, expected returns, risk control measures, and impact on company operations. The document is not a financial report like an annual or interim report, nor is it a call transcript or management report. It is a formal announcement about capital management activities, specifically cash management of idle funds and raised funds. This fits best under the category of Capital/Financing Update (CAP), as it relates to updates on company financing activities and capital usage. The document length is sufficient and contains substantive details about the financing activities rather than just a brief notice or regulatory filing. Therefore, the classification is CAP with high confidence.
2018-09-18 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.